Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?

Srinivasa P. Munigoti, C. V. Harinarayan
Consultant Endocrinologist, Fortis Hospital, 1Director, Institute of Endocrinology, Diabetes and Osteoporosis, Sakra World Hospitals, Marathahalli, Bangalore, Karnataka, India

ABSTRACT

A triad of high triglycerides, low high-density lipoprotein (HDL) cholesterol, and elevated small dense low-density lipoprotein particles occurring in a patient with type 2 diabetes is referred to atherogenic diabetic dyslipidemia (ADD). Despite statin therapy, a significant residual risk remains potentially attributable to increased triglyceride concentration and low HDL cholesterol, a characteristic hallmark of ADD. Current therapeutic options in reducing this residual risk include nicotinic acid, omega 3 fatty acids, and selective peroxisome proliferator-activated receptor-alpha (PPAR) agonists (fibrates). These drugs are limited in their potential either by lack of evidence to support their role in reducing cardiovascular events or due to their side effects. This review details their current status and also the role of new glitazar, saroglitazar adual PPARα/γ agonist with predominant PPARα activity in the management of ADD.

Key words: Atherogenesis, diabetic dyslipidemia, proliferator-activated receptor-alphas, saroglitazar

INTRODUCTION

A triad of high triglycerides, low high-density lipoprotein (HDL) cholesterol and elevated small dense low-density lipoprotein particles occurring in a patient with type 2 diabetes is referred to atherogenic diabetic dyslipidemia (ADD). Insulin resistance at the level of adipocyte causing increased free fatty acid efflux is thought to be central to the pathogenesis of ADD. This results in increased very LDL (VLDL) cholesterol from the liver facilitated by increased synthesis of coprotein apo B.[1] Subsequent actions mediated by cholesterol ester transferase protein in transferring triglycerides from VLDL particles to HDL and LDL result in increased apo A1 containing small dense HDL and apo B containing small dense LDL particles. The triglyceride-enriched HDLs subsequently hydrolyzed by hepatic lipase or lipoprotein lipase resulting in low HDL; Apo A-I dissociates from the reduced-size HDL, which is filtered by the renal glomeruli and degraded in renal tubular cells.[2,3] [Figure 1].

Reducing LDL cholesterol (C) using statins is a proven strategy for primary as well as secondary prevention of cardiovascular events. Hence, statin therapy is accepted as a first line in management of dyslipidemia, diabetic, or otherwise. But, despite statin therapy, a significant residual risk remains potentially attributable to increased triglyceride concentration and low HDL cholesterol, a characteristic hallmark of ADD. A meta-analysis of 14 trials involving statins that included 18,686 people with diabetes proved that presence of low HDL and high triglyceride limits the efficacy of statin therapy alone in reducing the vascular events despite achieving target LDL-C levels.[4] Similarly, a meta-analysis of 17 prospective studies showed that after adjusting for variables such as HDL-C, total cholesterol, and other risk factors, the relative risk for coronary heart disease with one mmol/L (1 mmol/L = 88.4956 mg/dL) increase in triglyceride was 1.14 [95% confidence interval (CI) 1.05-1.28] for men and 1.37 (95% CI 1.13-1.66) for women.[5] This has led to renewed interest in treatments...
that could selectively target high triglycerides and low HDL, thus, further reducing the cardiovascular risk. Omega 3 fatty acids, nicotinic acid, and fibrates are currently available drugs used to target such dyslipidemia.

ADD-Therapeutic Options

Omega 3 fatty acids
A systematic review and meta-analysis of available evidence studying the merits of omega 3 fatty acid supplementation mainly, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) have failed to show any cardiovascular benefit.[6] Similarly, recently published randomized placebo controlled “ORIGIN trial (Outcome Reduction With Initial Glargine Intervention)” that included patients with dysglycemia (N: 12,536) showed no cardiovascular benefits in the study population exposed to omega 3 fatty acid compared to placebo during the study period of over 6 years. This is despite significant reduction (P < 0.001) in triglyceride concentration in study arm compared to placebo (23.5+/-.3 mg/dL vs. 9+/-.3 mg/dL). It is of interest though to note that baseline triglyceride value in both groups in this study was around 140 mg/dL.[7] ASCEND (AStudy of Cardiovascular Events in Diabetes) a large placebo-controlled randomized prospective trial involving about 15,000 patients with diabetes in currently underway looking at the efficacy of 1 g capsules containing 90% omega 3 fatty acids (0.4 g EPA, 0.3 g DHA) as a primary preventive measure against cardiovascular events in patients with diabetes mellitus (Clinicaltrails.gov: NCT00135226).

Nicotinic acid
Nicotinic acid in extended release preparation (2 g/day) has been proven to increase HDL cholesterol by 20% and reduce triglyceride concentration by 25% in addition to lipid lowering by statin therapy.[8] Clinical utility of niacin is primarily limited by significant side effects such as severe facial flushing and cutaneous rash that are thought to be mediated by prostaglandins. Liropiprant a prostaglandin receptor antagonist was designed as a codrug to minimize these unpleasant side effects.[9] But, more recently “HPS2 THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events)” study done to assess the cardiovascular benefit of nicotinic acid/liropiprant combination in addition to statin +/- ezetimibe with a prestudy LDL cholesterol concentration of <130 mg/dL on over 40,000 patients across the globe showed highly significant four fold increased risk of myopathy in the study group compared to placebo and also double (0.9-0.4%) the incidence of diabetic complications (typically hyperglycemia)[10] needing early termination of the study raising serious concerns about the safety of this approach.

Peroxisome proliferator-activated receptor agonists
Peroxisome proliferator-activated receptor-alpha (PPARα), gamma (PPARγ), and beta/delta (PPAR β/γ) agonists regulate gene transcription by binding to specific deoxyribonucleic acid response elements upon ligand activation and heterodimerization with 9-cis retinoic acid receptor. Depending on the activating ligand, different receptor conformations are adopted, leading to different coactivator recruitment and subsequent effects on gene expression. Even though all the PPAR agonists are from the same pharmaceutical class, their biological activity varies widely based on selective alpha or gamma modulation.[11,12] PPARα regulates expression of genes encoding enzymes and transport proteins controlling lipid metabolism and is expressed predominantly in tissues with a high capacity for fatty acid oxidation like liver, heart, skeletal muscle, brown fat, and kidney. PPARγ not only promotes pre-adipocyte differentiation, but also induces adiponectin expression, which increases fatty acid oxidation by activation of the AMP-activated protein kinase pathway and down regulates the expression of genes encoding resistin and tumor necrosis factor together contributing to reduced insulin resistance.[13-15] While PPARγ agonism reduces insulin resistance, PPARα agonism compliments it by reducing the FFA load on peripheral tissues thereby augmenting glucose uptake.[16] PPARα and PPARγ receptors have also been found in vascular endothelium, monocytes/macrophages, and smooth muscle cells of vascular lineage exerting specific anti-inflammatory and lipid modulating effects supporting their role in antiatherogenesis[17] Figure 2.

Glitazones
Predominant PPARγ agonists recognized as “Glitazones” proven to improve insulin resistance have been used

Figure 1: High concentration of VLDL-transported TG triggers CETP mediated transfer of LDL cholesteryl ester or HDL cholesteryl ester in exchange for TG. Triglyceride-rich HDL cholesterol or LDL cholesterol then undergoes hydrolysis by hepatic lipase or lipoprotein lipase. Abbreviations: ApoA-I, apolipoprotein A-I; ApoB, apolipoprotein B; CE, cholesteryl ester; CETP, cholesteryl ester transfer protein; FFA, free fatty acid; HL, hepatic lipase; LPL, lipoprotein lipase; SD LDL, small dense LDL cholesterol; TG, triglyceride. Nature Clinical Practice Endocrinology and Metabolism (2009)5, 150-159
as antidiabetic agents for a few years now. Ciglitazone was first of this kind synthesized in 1982. Pioglitazone, englitazone, troglitazone, rosiglitazone, and darglitazone were synthesized later and among these, Troglitazone, Pioglitazone, and Rosiglitazone were evaluated in clinical studies.[18] Troglitazone was approved for clinical use 1997 but were subsequently withdrawn with in 3 years because of idiosyncratic liver toxicity.[19] Rosiglitazone was withdrawn from Indian market in 2010 secondary to cardiovascular concerns.[20] Pioglitazone although is still available to be prescribed, but concern regarding increased risk of bladder cancer on cumulative exposure[21] and risk of osteoporosis in women[22] has limited its potential for widespread use. Because of predominant PPARγ agonism, these agents have minimal influence if any on ADD.

**Fibrates**

Predominant PPARα agonists, “fibrates” as they are known, are proven to influence lipid profile but their role in ADD is extensively debated. Meta-analysis of several trials involving fibrates by Sacks et al.,[23] (ACCORD, FIELD, BIP, HHS, VA-HIT) showed that fibrates are very likely to be beneficial as an add on therapy in subgroup of patients characterized by high triglycerides and low HDL cholesterol despite statin usage. Similar systematic review on usefulness of fibrate therapy by Jun et al.,[24] demonstrated that those patients with a high mean triglyceride concentration obtained greater reduction in cardiovascular outcomes. All fibrates (except gemfibrozil) have shown reversible elevation of creatinine (up to 30%) of unknown significance.[25] In another meta-analysis, combination therapy with statin and fibrate was shown to be safe with no increased risk of serious myopathy or rhabdomyolysis.[26] Despite lack of any significant influence on PPARγ receptors, fibrates were shown to have some positive influence on glucose metabolism probably secondary to their influence on insulin resistance[27] but clinical outcome study proving their usefulness in improving glycemic control in addition to dyslipidemia is lacking.

**Glitazars**

A combined PPARα/γ agonist should ideally be a suitable drug in treatment of type 2 diabetic patients on statin therapy who have residual cardiovascular risk secondary to elevated triglyceride concentration. This molecule would not only target the dyslipidemia but also contribute to improved glycemic control. Given these benefits of dual PPARα/γ agonism, several pharmaceutical agents with such action commonly named as “glitazars” have been developed.

Depending on their molecular structure, these molecules exert dual action with varying degrees of PPARα and PPARγ activation. Faglitazar, the first glitazar to be tested, was dropped very early on in development phase secondary to significant edema.[28] Similarly, ragaglitazar was also dropped early on due to its carcinogenic potential on urothelial cells in rodent models.[29] Muraglitazar,[30] although proved successful in improving insulin sensitivity and treating diabetic dyslipidemia, was suspended in 2006 due to significant cardiovascular side effects. Tesaglitazar[31] showing similar promise was withdrawn secondary to its bone marrow and renal toxicities. Although these tested molecules resulted in adverse events, these have been compound specific and of diverse origin, that is, urothelial, renal, and cardiac rising hopes of a potential drug that could mitigate these side effects and yet have a positive influence on insulin sensitivity and dyslipidemia dominated by high triglycerides, small dense LDL and low HDL cholesterol Figure 3.

Saroglitazar, also a dual PPARα/γ agonist with predominant PPARα activity, is considered novel and unique as it was conceptualized to deliver antidiyslipidemic and antihyperglycemic effects without any of the adverse events of its predecessor molecules.[32] In a phase 1 study designed to evaluate pharmacokinetics, safety and tolerability of the drug, healthy volunteers were subject to varying doses of saroglitazar (0.25-128 mg/day). The drug was confirmed...
to have hepatobiliary excretion as a predominant route. All doses were very well-tolerated with no serious adverse events (renal/hepatic/cardiac) reported in the study group.\textsuperscript{[34]} Similarly in a 16-week (4 week wash out phase) multicenter, randomized, placebo-controlled, phase 3 trial of diabetic patients on treatment with atorvastatin 10 mg and with residual dyslipidemia consisting of triglycerides of >200 and <500, subjects were put to 12-week therapy with 2 and 4 mg of saroglitazar. At the end of 24 weeks, the results showed statistically significant reduction in triglyceride concentration (-45.5 mg/dL +/- 3.03%) with 2mg/d of saroglitazar + atorvastatin and similar reduction (-46 mg/dL mg/dL +/- 3.02%) in those on 4 mg/day of saroglitazar + atorvastatin compared with those on placebo + atorvastatin.\textsuperscript{[34]} Although non significant in statistical terms, patients in study group reduced glycated hemoglobin levels by 0.3/+/-0.08% with 2 mg/day and 0.2+/-0.07% with 4 mg/day dosage. At the end of 24 weeks, study group reported no significant renal, hepatic, and cardiac adverse events.

For now as observed in phase 1 and phase 3 trials, saroglitazar appears safe and has not shown any of the adverse effects that are commonly recognized with its class of molecules (e.g. Muraglitazar-cardiovascular and Tesaglitar-renal and bone marrow). But given historical concerns, proof of long-term safety remains paramount and is yet to be proven. Although, it has shown positive results in improving glycemic and lipid parameters in patients with ADD in short term, a longer term clinical trial proving its efficacy in improving cardiovascular outcome is currently nonexistent but much desired. Until such time given recent approval of saroglitazar by Indian authorities permitting its clinical use in treatment of ADD, both the pharmaceutical industry and medical profession should exercise close pharmacovigilance and report any adverse events as soon as observed.

**REFERENCES**

1. Lewis GF. Fatty acid regulation of very low density lipoproteins production. Curr Opin Lipidol 1997;8:146-53.
2. Bruce C, Chouinard RA Jr, Tall AR. Plasma lipid transfer proteins, high-density lipoproteins and reverse cholesterol transport. Annu Rev Nutr 1998;18:297-330.
3. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495-506.
4. Cholesterol Treatment Trialists’ (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet 2008;371:117-25.
5. Hokansen JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol level: Meta analysis of population based prospective studies. J Cardiovasc Risk 1996;3:213-9.
6. Ritzes EC, Ntzani EE, Bikai E, Kostapanos MS, Elisaf MS. Association between omega 3 fatty acid supplementation and risk of major cardiovascular disease events: A systematic review and meta-analysis. JAMA 2012;308:1024-33.
7. ORIGIN Trial investigators, Bosch J, Gerstein HC, Dagenais GR, Diaz R, Dyarian L, Jung H, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367:309-18.
8. Macaubbin D, Bays HE, Olson AG, Elinoff V, Elia A, Mitchell Y, et al. Lipid modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolemia or mixed dyslipidaemia. Int J Clin Pract 2008;62:199-70.
9. Lai E, De Lepeleire I, Cumley TM, Liu F, Wenning LA, Michiels N, et al. Suppression of niacin-induced vasodilatation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther 2007;81:949-57.
10. HPS2 THRIVE collaborative group. HPS2-THRIVE randomized placebo-controlled trial in 25, 673 high risk patients of ER niacin/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34:1279-91.
11. Duez H, Lefebvre B, Poulain P, Torre IP, Penuvart F, Luc G, et al. Regulation of human apoA-1 by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler Thromb Vasc Biol 2005;25:585-91.
12. Camp HS, Li O, Wise SC, Hong YH, Frankowski CL, Shen X, et al. Differential activation of peroxisome proliferator-activated receptor gamma by troglitazone and rosiglitazone. Diabetes 2000;49:539-47.
13. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005;54:2460-70.
14. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006;116:571-80.
15. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W. From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at crossroads of key cellular functions. Prog Lipid Res 2006;45:120-59.
16. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat fed rats: Comparison with PPAR gamma activation. Diabetes 2001;50:411-7.
17. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: Regulators of gene expression in vascular cells. Circ Res 2004;94:1168-78.
18. Larsen TM, Toubro S, Astrup A. PPARGamma agonists in the treatment of type II diabetes: Is increased fatness commensurate with long-term efficacy? Int J Obes Relat Metab Disord 2003;27:147-61.
19. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005;4:489-99.
20. Drugs banned in India. Central drugs standard control organization, dte.ghs, ministry of health and family welfare, government of india. [Retrieved on 2013 Dec 11].
21. Colmers IN, Bowker SL, Johnson JA. Thiazolidinedione use and fractures in type 2 diabetes: A meta-analysis. Diabetes Metab 2012;38:475-84.
22. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: A meta-analysis. CMAJ 2009;180:32-9.
23. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med 2010;363:692-4.
24. Jun M, Foote C, LV J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: A systematic review and meta-analysis. Lancet 2010;375:1875-84.
25. Davidson MH, Armani A, McKenny JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007;99:3-18C.
26. Guo J, Meng F, Ma N, Li C, Ding Z, Wang H, et al. Meta-analysis of safety of co administration of statin with fenofibrate in patients with combined hyperlipidemia. Am J Cardiol 2012;110:1296-301.

27. Damci T, Tatliagac S, Osar Z, Ilkova H. Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia. Eur J Intern Med 2003;14:357-60.

28. Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, Collin JL, et al. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J Med Chem 1998;41:5020-36.

29. Egerod FL, Nielsen HS, Iversen L, Thorup I, Storgaard T, Oleksiewicz MB. Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo. Biomarkers 2005;10:295-309.

30. Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belderet R, Grossal J, et al. Improvement in glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double blind, randomized, pioglitazone-comparative study. Diabetes Care 2006;29:1016-23.

31. Fagerberg B, Edwards S, Halmos T, Lopatynsky J, Schuster H, Stender S, et al. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia 2005;48:1716-25.

32. Agrawal R. The first approved agent in the Glitazar’s class: Saroglitazar. Curr Drug Targets 2014;15:151-5.

33. Jani RH, Kansagra K, Jain MR, Patel H. Pharmacokinetics, safety and tolerability of saroglitazar (ZHY1), a predominantly PPARrx agonist with moderate PPARγ agonist activity in healthy human subjects. Clin Drug Invest 2013;33:800-16.

34. Jani RH, Pai V, Jha P, Jariwala G, Muthupadhyay S, Bhansali A, et al. A multicenter, prospective, randomised, double blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled on atorvastatin therapy (PRESS VI). Diabetes Technol Ther 2014;16:63-71.

Cite this article as: Munigoti SP, Harinarayan CV. Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?. Indian J Endocr Metab 2014;18:283-7.

Source of Support: Nil, Conflict of Interest: None declared.